9 February 2017 - The U.S. FDA today approved Emflaza (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle deterioration and weakness. 

Emflaza is a corticosteroid that works by decreasing inflammation and reducing the activity of the immune system.

Corticosteroids are commonly used to treat Duchenne muscular dystrophy across the world. This is the first FDA approval of any corticosteroid to treat Duchenne muscular dystrophy and the first approval of deflazacort for any use in the United States.

Read FDA press release